Comparison of the effects of crizotinib as monotherapy and as combination therapy with butyric acid on different breast cancer cells

Topçul M. R., Çetin İ., Pulat E., Çalışkan M.

ONCOLOGY LETTERS, vol.29, no.38, pp.1-10, 2025 (SCI-Expanded)

  • Publication Type: Article / Article
  • Volume: 29 Issue: 38
  • Publication Date: 2025
  • Doi Number: 10.3892/ol.2024.14784
  • Journal Name: ONCOLOGY LETTERS
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS
  • Page Numbers: pp.1-10
  • Istanbul University Affiliated: Yes

Abstract

In recent years, there have been significant developments using combined therapies in cancer treatment. The present study aimed to determine the effects of using crizotinib alone and in combination with butyric acid on different types of breast cancer cells. A total of three different breast cancer models were used: MDA‑MB‑231, a triple negative model; MCF‑7, a Luminal A model; and SKBR‑3 cell line, a human epidermal growth factor receptor 2 positive model. In the experiments, proliferation rates and cell index values were obtained using the xCELLigence RTCA DP System, and mitotic index, bromodeoxyuridine labeling index and caspase activity were evaluated as cell kinetics parameters. The results showed that while proliferation rates, cell index values, mitotic index and bromodeoxyuridine labeling index decreased, caspase activity values increased. These results demonstrated that the combined application was more effective than the monotherapy application and could be used at lower concentrations than those drugs applied as monotherapy